Most coverage of retatrutide leads with the number that sells: up to ~28.3% average body weight loss at 12mg over 80 weeks in TRIUMPH-1. Far less attention goes to the other half of the file — who couldn't stay on the drug long enough to get there. Two fresh phase 3 readouts, TRIUMPH-2 and TRIUMPH-3, reported in topline form in July 2026, have quietly changed how the retatrutide side effects conversation should sound in Australia. The headline finding isn't a new symptom. It's that the dose people quit at isn't the dose you'd expect.

The new data: five positive phase 3 trials, one messy tolerability curve

Eli Lilly's July 2026 topline release covered two more pivotal studies, reporting weight reductions of up to 22.6% alongside A1c improvements, and taking retatrutide to five positive phase 3 studies. The side-effect profile was familiar and firmly gastrointestinal: diarrhoea, nausea, constipation, decreased appetite and vomiting, most of which resolved during treatment.

The interesting part is the discontinuation data — people who stopped the drug because of adverse events:

  • TRIUMPH-2: 3.8% (4mg), 11.6% (9mg), 7.7% (12mg) versus 4.9% on placebo
  • TRIUMPH-3: 9.8% (9mg) and 13.5% (12mg) versus 4.8% on placebo

Read that TRIUMPH-2 row again. The 9mg arm shed more people than the 12mg arm. That is not what a simple "more drug, more side effects" model predicts, and it's a reminder that trial arms differ in escalation schedules, population and chance. Two caveats matter enormously here: these are topline company figures from a press release, not peer-reviewed publications, and detailed results are still to be presented at medical meetings and published. Until then, treat the ordering of those percentages as provisional.

What is consistent across all five studies is the shape of the problem: roughly 4–14% of participants on active drug stopped for tolerability reasons, against a placebo floor of around 5%. Meaning the great majority tolerated it — but a real minority did not, and that minority grows as the dose climbs. More on the underlying pharmacology in what is retatrutide.

Why the escalation curve matters more than the peak dose

Retatrutide adds glucagon receptor agonism on top of GLP-1 and GIP. That third receptor is a big part of why the weight loss numbers outrun semaglutide (Ozempic/Wegovy, one receptor) and tirzepatide (Mounjaro/Zepbound, two). It also brings effects that single- and dual-agonists don't emphasise — a modest resting heart rate rise reported in earlier trial data, and dysesthesia (tingling or altered skin sensation) reported at higher doses. Both have been described in published phase 2 work and secondary reporting on phase 3; neither has a settled long-term picture yet, which is exactly why the peer-reviewed TRIUMPH publications matter. Our running summary sits at clinical trials and safety.

The practical implication: for retatrutide, the target dose is a destination, not a starting point. Slower titration, dose pauses and stepping back a level are the standard levers, and the trial data suggests they're the difference between finishing a programme and abandoning it in month three.

Retatrutide side effects in an Australian care model

Here's where this genuinely lands differently in Australia. Around 66.8% of Australian adults are overweight or obese, and if retatrutide is eventually registered here, the volume simply cannot be absorbed by endocrinologists and specialist obesity clinics. It will be a GP medicine, delivered in 15-minute consults, often with months between reviews and long waits in regional and remote areas.

That's a tolerability system, not just a drug. Three things follow:

1. Titration support is the access issue nobody costs in

A patient who is nauseated at week six and can't get an appointment until week eleven is a patient who stops. Countries with structured pharmacist-supported titration and nurse check-ins are likely to see fewer dropouts than the raw trial figures suggest is necessary. Australia's GP-led model can do this well — but only if it's resourced deliberately.

2. Trial patients aren't Australian clinic patients

TRIUMPH participants were screened, monitored and reviewed on a schedule. Real-world discontinuation for GLP-1 medicines in Australia has generally run higher than trial figures. Expect the same gap here.

3. Nothing above is prescribable in Australia today

Retatrutide is investigational. It is not TGA-approved, and Eli Lilly has said it plans to submit for US approval from Q1 2027, with other regulators following. Any Australian pathway runs after that. Details at retatrutide Australia.

What to actually do with this information

If you're planning ahead, the useful work is unglamorous: get a GP relationship established now, sort out what your baseline metabolic picture looks like, and understand that the first eight to sixteen weeks on any incretin therapy are the ones that decide whether you stay on it. Those habits transfer directly to currently available treatments.

We publish plain-English updates whenever new TRIUMPH data, publications or regulatory movement land — join the free updates list.

FAQ

What are the most common retatrutide side effects?

Across the phase 3 TRIUMPH programme, the most commonly reported effects were gastrointestinal: diarrhoea, nausea, constipation, decreased appetite and vomiting, with most resolving during treatment. Higher doses have also been associated with a modest heart rate increase and, at 12mg, reports of dysesthesia (tingling or altered skin sensation).

How many people stop taking retatrutide because of side effects?

In the July 2026 topline results, discontinuation due to adverse events ranged from about 3.8% to 13.5% across retatrutide doses, compared with roughly 4.8–4.9% on placebo. These are company topline figures pending peer-reviewed publication.

Is retatrutide available in Australia yet?

No. Retatrutide is investigational and has not been approved by the TGA. Eli Lilly plans to file for US approval from 2027, and any Australian registration and PBS consideration would follow after that.

Are retatrutide side effects worse than Ozempic or Mounjaro?

The side-effect categories are broadly similar to other incretin medicines, but retatrutide's glucagon component adds effects such as heart rate increase and dysesthesia that are less prominent with semaglutide or tirzepatide. No head-to-head tolerability comparison has been published, so direct claims either way aren't supported yet.

Sources

This article is general information only and is not medical advice. Retatrutide is an investigational medicine that is not approved by the TGA and is not available on prescription in Australia. Speak to your GP or a qualified health professional about your own circumstances. retatrutide.net.au is an independent Australian information site and is not affiliated with, endorsed by or sponsored by Eli Lilly and Company.